top of page
Research Interests and Clinical Trials


Link to Pubmed 

  1. Primary / Co-Investigator (Investigator Initiated – ongoing)

    1. ATTRaCT - Asian neTwork for Translational Research and Cardiovascular Trials (NCT 02791009)

    2. SAVIOUR - Biomarkers and Management of Cardiovascular Disease

      1. SAVIOUR-AS Biomarker Evaluation in Aortic Stenosis

      2. SAVIOUR-MR Biomarker Evaluation in Mitral Regurgitation

      3. SAVIOUR-MVP Proteomics Discovery of Biomarkers for Mitral Valve Prolapse and Biobanking DNA for Genetic Studies in Mitral Valve Prolapse

    3. ASIAN-HF registry – (NCT01633398)

    4. SingCLOUD - Long-term clinical outcomes, cost-of-care, clinical characteristics, re-admission rates, outpatient care and mortality in patients with coronary artery disease or congestive heart failure in Singapore (SINGCLOUD for Singapore Cardiac Longitudinal OUtcomes Database Study) (DSRB - 2013/00462)

  2. Primary / Co-Investigator (Industry Initiated - ongoing)

    1. VICTORIA - A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001). (NCT02861534)

  3. Primary Investigator (Investigator Initiated – completed)

    1. CLOPRA: CLOpidogrel-PRAsugrel switch study in Southeast-Asian Acute Coronary Syndrome requiring PCI: A Cost Effectiveness Study

    2. CONTRAST (COmbined acetylcysteine and bicarbonate in Cardiac Catheterisation To Reduce Adverse Side effect of contrasT) – (NCT 00497328)

    3. Development and evaluation of the nurse-led telephone follow-up program in post-acute coronary syndrome patients.(DSRB - 2013/00666)

    4. SAFE: Singapore Armed Forces Echocardiogram and ECG study

    5. PEOPLES – Prospective Evaluation of Outcome for Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction.

    6. SHOP - Singapore Heart Failure Outcomes and Phenotypes

    7. Genotype-Guided Warfarin Dosing (WarfGen) in Local Patients Initiating Oral Anticoagulation: a Quality Assurance Study. (DSRB - 2013/00160)

    8. P2Y12 inhibitors in Acute Coronary Syndrome (PACS): Ticagrelor in ST-Elevation Myocardial Infarction. (DSRB - 2012/01137)

    9. ASThein-DI: Asian Study of Thienopyridine-Drug Interactions

    10. Assessment of myocardial perfusion imaging with cardiac CT. (DSRB 2013/00004)

  4. Primary / Co-Investigator (Industry Initiated - completed)

    1. ODYSSEY Outcomes - Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) - Site 702003. (NCT01663402)

    2. FOURIER - Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk. (NCT01764633)

    3. COMPARE-ACUTE- Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD. (NCT01399736)

    4. CL2-38844-010 -  Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunction - A phase II, randomised, double-blind, parallel-group, placebo controlled, international multicentre study (EudraCT: 2013-003000-39)

    5. SOCRATES-REDUCED - Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (NCT01951625)

    6. SOCRATES-PRESERVED -  Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (NCT01951638)

    7. PARADIGM-HF (LCZ696B2314) – A multi-center, randomised, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 therapy compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II – IV) with reduced systolic function – (NCT01035255)

    8. X-VERT - Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion – (NCT01674647)

    9. AVERROES (Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment:  A Randomized Double Blind Trial) – (NCT 00496769)

    10. ROCKET AF (A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (Bay 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation) – (NCT00403767)

    11. CL3- 05985-018 - Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive strategies: Efficacy and safety in mild to moderate hypertensive patients. A randomised, double-blind 6-month study followed by 8-month open label long-term follow-up with Perindopril arginine/Amlodipine.

    12. AFFILIATE  (A1481324) - A multinational, multicenter study to assess the effects of oral sildenafil on mortality in Adults with Pulmonary Arterial Hypertension (PAH). (EudraCT: 2013-004362-34, NCT02060487)

    13. PARAGON-HF - Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction. (NCT01920711)

  5. Co-investigator in Phase III clinical drug studies (completed)

    1. Val-Heft (Valsartan in Heart Failure) 1998

    2. CHARM (Candesartan Cilexetil in Heart Failure: Assessment of Reduction in Mortality and Morbidity) - (NCT00634400, NCT00634309, NCT00634712) 1998

    3. IONA (Impact of Nicorandil in Angina) 1998

    4. OVERTURE (Omapatrilat versus Enalapril Randomised Trial of Utility in Reducing Events) 1998

    5. RECOVER (Research into ENBREL: Cytokine Antagonism in Ventricular Dysfunction) 1998

    6. CRESCENDO (Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes) 2005

    7. Trilogy ACS (H7T-MC-TABY) - A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed – (NCT00699998)

    8. APPRAISE-2 (Apixaban for Prevention of Acute Ischemic Events) - A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome – (NCT00831441)

    9. ASTRONAUT (CSPP100A2368) - A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality when initiated early after hospitalization for acute decompensated heart failure - NCT00894387

    10. PARAMOUNT (LCZ696B2214) -  A twelve-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction

bottom of page